Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Librera OncoLink / Repaso de Diarios / Cáncer de Pulmón
|
A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer
Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J, Olazabal A, et al. N Engl J Med 1994 Jan 20;330(3):153-8 The classic paper by Rosell et al addresses one of the more vexing issues in the treatment of lung... |
|
|
A Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIA Non-Small-Cell Lung Cancer
Authors: Keller SM, Adak S, et al. Source: New England Journal of Medicine 2000; 343(17): 1217-22. Background In patients with surgically resected NSCLC (non-small-cell lung cancer), spread of the tumor to intrathoracic lymph nodes significantly... |
|
|
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer
Authors: The International Adjuvant Lung Cancer Trial Collaborative Group Source: New England Journal of Medicine (2004) Volume 350, Issue 4, Pages 351-360 Introduction In the United States, lung cancer accounted for an estimated 171,900 new... |
|
|
Determinants of Long Term Survival after Surgery for Cancer of the Lung
Reviewers: Li Liu, MD Source: Cancer, Volume 86, No. 11 (December): 2229-2237, 1999.Précis: Prognostic factors of lung cancerIntroductionPatient age, extent of the disease, and performance status at diagnosis are major prognostic determinants... |
|
|
Effect of Cigar Smoking on the Risk of Cardiovascular Disease, Chronic Obstructive Pulmonary Disease and Cancer in Men
Reviewers: Kenneth Blank, MD Source: The New England Journal of Medicine June 10, 1999 Vol. 340, No. 23, p.1773IntroductionThe association between cigarette smoking and cancer is well established and the efforts of various organizations have... |
|
|
Environmental Tobacco Smoke and Lung Cancer: A Case-Control Study in Germany
Reviewers: Li Liu, MD Source: American Journal of Epidemiology, Volume 151:241-250, (February) 2000Précis: Nonsmokers' exposure to tobacco smoke in public places associated with increased lung cancer riskIntroductionDuring the last 2... |
|
|
Induction Chemotherapy before surgery for Early-Stage Lung Cancer: A Novel Approach
Reviewers: Li Liu, MD Source: Journal of Thoracic Cardiovascular Surgery, Volume 119:429-439, (March) 2000Précis: Induction chemotherapy before surgery is effective for non small-cell lung cancerIntroductionDespite an encouraging decline in... |
|
|
Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B
Source: J Clin Oncol. 2007 May 1; 25 (13):1698-1704 Authors: Vokes, EE; Herndon, JE II; Kelley, MJ; Cicchetti, MG; Ramnath, N; Neill, H; Atkins, JN; Watson, DM; Akerley, W and Green, MR Background Standard therapy currently for... |
|
|
Lung Cancer Mortality in the Mayo Lung Project: Impact of Extended Follow-up
Reviewers: Li Liu, MD Source: Journal of the National Cancer Institute, Volume 92:1308-1316, (August) 2000Précis: Screening does not reduce long-term lung cancer mortalityIntroductionAt present, there is widespread acceptance that screening... |
|
|
Non-occupational exposure to chrysotile asbestos and the risk of lung cancer
Reviewers: Kenneth Blank, MD Source: The New England Journal of Medicine, May 28, 1998 Vol 338, No. 22, p.1565BackgroundAsbestos is a mineral fiber, which has many forms. Chrysotile, which is mined primarily in Quebec Canada, is the most common... |
|
|
Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I (Except T1N0), II, and IIIa Non-Small-Cell Lung Cancer
Authors: A Depierre, B Millerson, D Moro-Sibilot, et al. Source: Journal of Clinical Oncology 2002; 20 (1): 247-53 Background Early stage non-small cell lung cancer (NSCLC) is usually treated with surgical resection. Although early stage... |
|
|
Recurrence of Bronchioloalveolar Carcinoma in Transplanted Lungs
Reviewers: Kenneth Blank, MD Source: The New England Journal of Medicine Volume 340, Number 14: April 8, 1999BackgroundBronchioloalveolar lung cancer is characterized pathologically by cancer cells lining the lung alveoli while... |
|
|
Study of Paclitaxel, Etoposide, and Cisplatin Chemotherapy Combined with Twice-Daily Thoracic Radiotherapy for Patients with Limited Stage Small Cell Lung Cancer: An RTOG 96-09 Phase II Study
Authors: David S. Ettinger, et. al. Authors' Affiliations: Radiation Therapy Oncology Group Journal: J Clin Onc 2005; August 1, 23(22):4991-98 Background Although Small Cell Lung Cancer (SCLC) is responsive to either chemotherapy or... |
|
|
Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer
Authors: Fried et al. Source: Journal of Clinical Oncology, Volume 22, Number 23, December 1, 2004 Introduction Meta-analyses by Payne, Pignon and Warde have helped to confirm the benefit of adding thoracic irradiation to chemotherapy for... |
|
|
Targeting of Lung Cancer Mutational Hotspots by Polycyclic Aromatic Hydrocarbons
Reviewers: Li Liu, MDSource: Journal of the National Cancer Institute volume 92, 803-811 (May) 2000IntroductionGasoline and diesel engines and other industrial sources release chemicals called polycyclic aromatic hydrocarbons (PAH's) into the... |
Dr. Giantonio discusses the importance of oncology clinical trials and clarifies some myths about studies. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

